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The transcription factor IRF4 regulates immuno-
globulin class switch recombination and plasma
cell differentiation. Its differing concentrations
appear to regulate mutually antagonistic programs
of B and plasma cell gene expression. We show
IRF4 to be also required for generation of germinal
center (GC) B cells. Its transient expression in vivo
induced the expression of key GC genes including
Bcl6 and Aicda. In contrast, sustained and higher
concentrations of IRF4 promoted the generation of
plasma cells while antagonizing the GC fate. IRF4
cobound with the transcription factors PU.1 or
BATF to Ets or AP-1 composite motifs, associated
with genes involved in B cell activation and the GC
response. At higher concentrations, IRF4 binding
shifted to interferon sequence response motifs;
these enriched for genes involved in plasma cell dif-
ferentiation. Our results support a model of ‘‘kinetic
control’’ in which signaling-induced dynamics of
IRF4 in activated B cells control their cell-fate out-
comes.
INTRODUCTION
Germinal Center (GC) B cells and plasma cells (PC) develop
following the activation of naive B cells with cognate antigen in
combination with signals from T helper cells and dendritic cells
(Goodnow et al., 2010). These distinct cellular states, GC and
PC, perform key roles in humoral immunity against microbes
by enabling generation of high-affinity antibodies and their
robust expression and secretion, respectively. Considerable
progress has been achieved in the analysis of transcription fac-
tors that are required for the generation of GC B cells and their918 Immunity 38, 918–929, May 23, 2013 ª2013 Elsevier Inc.plasma cell counterparts; however, the molecular mechanisms
by which such regulators orchestrate these alternative cellular
states and the transition from the GC to the PC differentiation
programs are incompletely understood.
The identity and function of plasma cells is dependent on the
transcription factors Blimp1, Xbp1, and IRF4 (Nutt et al., 2011).
In contrast, GC B cell development requires the transcription
factors Bcl6, Pax5, Bach2, and Obf1 (Nutt et al., 2011). Blimp1
and Bcl6 function to counter regulate each other’s expression.
This reciprocal negative feedback is considered to play a major
role in stabilizing the alternate programs of gene expression.
We have proposed that the transcription factor IRF4 is a
pivotal regulator of B cell-fate dynamics upon antigen encounter
(Sciammas et al., 2006, 2011). This is based on our findings that
IRF4 is required for class switch recombination (CSR) and
plasma cell differentiation. It does so by upregulating AID and
Blimp1 expression, respectively. We have demonstrated, by us-
ing a variety of approaches, that differing IRF4 concentrations
underlie the generation of these alternative cell states. These
experimental analyses have led to the formulation of a ‘‘kinetic
control’’ model for the regulation of B cell-fate dynamics span-
ning the CSR and plasma-cell states (Sciammas et al., 2011;
see also Muto et al., 2010). According to this model, the rate of
accumulation of IRF4 induced by the BCR determines the dura-
tion for which such a cell expresses AID and therefore can un-
dergo CSR and also somatic hypermutation (SHM). Increased
expression of IRF4 beyond a critical threshold results in IRF4
activation of the Prdm1 (encoding Blimp1) locus and terminal dif-
ferentiation into a plasma cell. This is accompanied by repres-
sion of Aicda (encoding AID) expression and CSR, as well as
SHM. However, it remains to be determined whether this regula-
tory model is applicable to T-dependent B cell responses in vivo.
It has been suggested that IRF4 is dispensable for the GC
response in vivo (Klein et al., 2006). However, this conclusion
was based on the use of a conditional allele of IRF4 whose dele-
tion is initiated after antigen encounter, raising the possibility that
IRF4 protein was not sufficiently depleted in precursors of GC B
cells in these mice. Therefore, we sought to address the role of
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genetic strategies.
IRF4 is a member of the IRF superfamily of transcription fac-
tors most highly related to IRF8 (Eisenbeis et al., 1995). Although
IRF8 is expressed in activated and GC B cells, it has been shown
to be dispensable for antigen-dependent B cell responses (Feng
et al., 2011). IRF4 and IRF8 bind with much lower affinity to the
GAAA motif contained within the canonical interferon sequence
response element (ISRE). Instead they are recruited to high affin-
ity Ets-IRF composite motifs (EICE) through their interaction with
the transcription factors PU.1 or SpiB (Brass et al., 1999; Eisen-
beis et al., 1995). The latter are related Ets family members that
play key roles in B cell activation and GC B cell function (Garrett-
Sinha et al., 2001; Su et al., 1997). Recently IRF4 and IRF8 have
shown to cooperatively assemble with BATF containing AP-1
complexes on composite AP-1-IRF (AICE) motifs (Glasmacher
et al., 2012). Intriguingly, IRF4 appears to activate the Prdm1
(Blimp1) locus by binding to a site within a conserved intronic
sequence that does not contain an EICE motif nor is associated
with PU.1 cobinding (Sciammas et al., 2006). These results
raised the possibility that alternate modes of IRF4 genome tar-
geting i.e., PU.1 or SpiB dependent and Ets factor independent
may be important in regulating distinct states of gene expres-
sion, GC versus PC, within activated B cells.
Herein, by using distinct genetic strategies we demonstrate
that IRF4 regulates the generation of GC B cells. It does so by
controlling the expression of the Bcl6 and Obf1 genes. Further-
more, whereas transient induction of IRF4 in vivo was sufficient
to induce GC B cells, sustained and higher concentrations of
IRF4 promoted the generation of plasma cells while antagonizing
the GC fate. To delineate IRF4 target genes and its modes
of genomic interaction that are reflective of the GC or plasma
cell programs, we performed chromatin immunoprecipitation
sequencing (ChIP-seq) analysis by using an antigen-specific B
cell culture system. Kinetic analysis of IRF4 binding to genomic
sites, with or without its DNA partner PU.1, was correlated with
changes in gene expression. Interestingly, IRF4 cotargeting
with PU.1 at EICE motifs was associated with genes involved
with B cell activation and the GC response. During these early
stages of B cell activation, IRF4 targeting was also associated
with AICE motifs. In striking contrast at a later stage, reflective
of plasma cells, IRF4 targeting shifted to lower affinity ISRE mo-
tifs that enriched for genes involved in plasma cell differentiation.
These results provide molecular insight into the concentration-
dependent modes of IRF4 action in regulating the GC and PC
programs of gene expression. Furthermore, they provide in vivo
support for our model of ‘‘kinetic control,’’ which posits that the
dynamics of accumulation of IRF4 in activated B cells regulate
cell-fate outcomes during a humoral immune response.
RESULTS
IRF4 Regulates GC B Cell Differentiation
To analyze requirement of IRF4 in GC B cell responses, we
generated mixed bone marrow chimeras with Irf4+/+ and Irf4/
progenitors (see Figure S1A available online). Following hemato-
poietic reconstitution, the animals were immunized with sheep
red blood cells (SRBC) to elicit a T-dependent GC B cell
response. Whereas the wild-type (WT) (CD45.1+CD45.2+)B220+ compartment contained CD95+GL7+ GC B cells, the
Irf4/ (CD45.2+) B220+ compartment lacked such cells (Fig-
ure 1A). Accordingly, Bcl6 expressing cells were not generated
within the Irf4/ population (Figure 1B). The defect in GC B
cell formation must be intrinsic to Irf4/ B cells because the he-
matopoietic compartment in these chimeric animals contains
WT T and dendritic cells. It has been suggested that B cells
from Irf4/ mice are developmentally immature based on
expression of CD23 and immunoglobulin M (IgM) (Mittru¨cker
et al., 1997). To exclude the possibility that the severe block in
GC B cell differentiation was simply due to a developmental
arrest at an immature stage, we analyzed Irf4/ B cells for
expression of CD93, a marker of immature and transitional B
cells (Allman et al., 2001). CD93 expression on splenic B cells
from Irf4+/ and Irf4/ mice was indistinguishable (Figure S1B).
Moreover, this analysis revealed the basis for the skewed distri-
butions of CD23 and IgM expression in Irf4/ mice to be likely
due to an increase in the proportions of marginal zone B cells
(Figures S1C and S1D). Thus the defect in GC B cell differentia-
tion caused by loss of IRF4 is not due to a developmental arrest
at an immature B cell stage.
Previously, we suggested that IRF4 was dispensable for GC B
cell differentiation based on analysis of Irf4fl/fl mice using a Cg1-
Cre driver that deletes after antigen stimulation of B cells (Klein
et al., 2006). The analysis did not rule out the possibility that in
this mouse model, the timing of Irf4 deletion and/or stability of
the residual IRF4 protein may have obscured its role in GC B
cell differentiation. To test this possibility, we crossed Irf4fl/fl
mice with CD19-Cre mice so that deletion of the Irf4 gene
occurred prior to antigen encounter. Importantly, earlier deletion
of Irf4 in B cells resulted in an impaired GC response (Figures 1C
and 1D). The conditional Irf4 allele activates GFP expression
concomitant with CRE-mediated deletion (Klein et al., 2006).
Staining of splenic tissue sections revealed that the few GCs
developing in Irf4fl/fl 3 CD19-Cre mice were GFP-negative, in
contrast with their controls, demonstrating that these residual
GCs were formed with B cells in which the Irf4 allele had not
been deleted (Figure 1D). Thus, IRF4 plays an essential and
cell-autonomous role in instructing GC B cell differentiation.
IRF4 Regulates Bcl6 and Pou2af1 during a GC B Cell
Response
To determine whether IRF4 regulates Bcl6 and Obf1 expression
within antigen-responding B cells in vivo, we bred the Irf4/
mouse to the SWHEL mouse in which the B cells are specific
for the Hen Egg Lysozyme (HEL) antigen (Phan et al., 2005).
SWHEL B cells from WT and Irf4
/ mice were adoptively trans-
ferred into CD45.1 mice, which were then immunized with the
intermediate affinity HEL2X coupled to SRBC (Figure S2A). Anal-
ysis of IRF4 and Bcl6 expression in WT SWHEL responder cells,
4.5 days later, revealed two subsets: IRF4loBcl6+ and
IRF4hiBcl6 (Figure 2A; Figure S2B). Because IRF4 is highly ex-
pressed in plasma cells, we confirmed that IRF4hiBcl6 popula-
tion represented plasma cells by their expression of cytoplasmic
anti-HEL Ig and reduced B220 (Figure S2C). In contrast, the
IRF4loBcl6+ population represented GC B cells based on high
expression of Bcl6 and B220. Importantly, Irf4/ SWHEL cells
did not generate either Bcl6 expressing cells or plasmablasts.
Notably, Irf4/ SWHEL B cells responded appropriately toImmunity 38, 918–929, May 23, 2013 ª2013 Elsevier Inc. 919
Figure 1. IRF4 Regulates GC B Cell Differentiation
(A and B) We generated 1:1 mixed bone marrow chimeras such that the CD45.1-expressing compartments in groups A and B were reconstituted with Irf4+/+
hematopoietic progenitors, whereas the CD45.2 expressing compartments were reconstituted with Irf4+/+ and Irf4/ hematopoietic progenitors, respectively.
Reconstituted mice were immunized with SRBC, and GC B cells were analyzed on Day 7 based on expression of GL7 and CD95 or intracellular Bcl6 expression
after gating onCD45 polymorphic alleles and the B cell lineagemarker B220 as indicated. Data are representative of two independent experiments using fivemice
per group.
(C) Conditional deletion of Irf4 in B cells using CD19-Cre. Indicated mice were immunized with SRBC and splenic GC B cells were analyzed on day 14 based on
expression of PNA and CD95 after gating on B220. Each point in the right panel represents the numbers of GC B cells from individual mice.
(D) Immunohistochemical analysis of GCs in mice described in (C). Splenic sections were stained for Bcl6, IgM, and GFP as indicated. See also Figure S1.
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divisions, albeit with reduced efficiency (Figure S2D) (Phan et al.,
2005). Thus, IRF4 plays an essential role in the generation of Bcl6
expressing cells in the context of antigen signaling and cognate920 Immunity 38, 918–929, May 23, 2013 ª2013 Elsevier Inc.T cell interactions in vivo. Furthermore, these results demon-
strate that antigen encounter leads to the generation of distinct
B cell states that can be discriminated on the basis of IRF4
and Bcl6 expression in vivo, which reflect mutual antagonism
Figure 2. IRF4 Regulates GC B Cell Differentiation via the Activation of the Bcl6 and Pou2af1 Genes
Irf4+/+ or Irf4/ SWHEL donor B cells were transplanted into CD45.1 hosts and immunized with HEL
2XSRBC.
(A) Four and a half days after immunization, donor-derived antigen specific cells were identified based on B220+CD45.2+CD45.1 phenotype and binding to HEL
antigen. Expression of IRF4 and Bcl6 expression was then analyzed by intracellular staining.
(B) Cells described in (A) were sorted, and RNA was analyzed by qRT-PCR. Indicated transcripts were normalized to those from Oct1 gene, and the data
represents the average ± SEM of three independent experiments with two mice per group.
(C) WT SWHEL donor B cells were adoptively transferred into CD45.1 hosts and immunized with indicated HEL variants conjugated to SRBC. Four and a half days
after immunization, donor derived antigen specific cells were identified and analyzed as in (A).
(D) Quantitative analysis of experiments described in (C). The ratio of HEL-specific IRF4hiBcl6 to IRF4loBcl6+ expressing cells for individual mice is plotted from
three independent experiments.
(E) ELISpot analysis of HEL-specific IgG secreting PC cells from experiments in (C); representative results are shown. See Figure S2 for quantitation.
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expression.
We then tested whether IRF4 was required for transcriptional
activation of theBcl6 andPou2af1 genes. SWHEL responder cells
were isolated 4.5 days following immunization (Figure S2D) and
their transcripts analyzed by quantitative RT-PCR (qRT-PCR).
Importantly expression of Bcl6 and Pou2af1 (encoding Obf1)
were severely compromised in Irf4/ SWHEL B cells compared
to their WT counterparts (Figure 2B). As expected, expression
of the Aicda and Prdm1 genes were also impaired (Klein et al.,
2006; Sciammas et al., 2006). We note that Pax5 transcripts
were comparable between Irf4/ SWHEL B cells and their WT
counterparts (Figure S2E). Thus, the Bcl6 and Pou2af1 genes,
which regulate GC B cell differentiation, are dependent on
IRF4 for their induced expression in B cells upon antigen
encounter in vivo.
Increased Antigen Affinity Favors Generation of IRF4hi
Plasma Cells
Previously we have shown that increased antigen affinity aug-
ments BCR signaling-mediated expression of IRF4 and thus
favors the generation of plasma cells at the expense of cells un-
dergoing CSR in vitro (Sciammas et al., 2011). Given ability to
analyze B cell dynamics in vivo on the basis of IRF4 and Bcl6
expression we tested whether varying antigen affinity in vivo
had the predicted consequences on GC and plasma cell states.
After adoptive transfer ofSWHEL cells,we immunizedwitha seriesof HEL variants that exhibit a 10,000 fold range in affinity for the
HyHEL10 BCR (Paus et al., 2006). The highest-affinity antigen
led to an increased proportion of IRF4hiBcl6 plasma cells (Fig-
ures 2C and 2D; Figure S2F). The enhancement in plasma cell
generationwas confirmed byHEL-specific ELISpot analysis (Fig-
ure2E;FigureS2G). Thus,both in vitroaswell as in vivo increasing
the intensityof signaling through theBCR leads togreater expres-
sion of IRF4 and favors the generation of plasma cells.
Transient Expression of IRF4 Induces Generation of
Bcl6 Expressing GC B Cells
To directly test consequences of manipulating IRF4 con-
centration on B cell-fate dynamics in vivo, we utilized a tet-induc-
ible allele (Sciammas et al., 2011) with the SWHEL transgenic
system. This transgene is engineered to express IRF4 in a tet-
responsive manner via the transcriptional activator (M2rtTA).
The tet-inducible Irf4 and SWHEL transgenes were crossed
onto the Irf4/ background so that the former functioned as
the sole source of IRF4 protein in vivo (Figure 3A). For the exper-
iments using Irf4-inducible SWHEL B cells, the CD45.1 host mice
were crossed with theM2rtTA allele to prevent rejection of trans-
planted cells due to the neo-antigen effects of the bacterial
transactivator protein. Following adoptive transfer of B cells
into CD45.1+Rosa+/M2rtTA congenic hosts and immunization
with intermediate affinity HEL2X, the mice were administered
doxycycline (DOX) either continuously (‘‘sustained’’) or just dur-
ing the first two days after immunization (‘‘pulsed’’). SustainedImmunity 38, 918–929, May 23, 2013 ª2013 Elsevier Inc. 921
Figure 3. Inducible expression of Irf4 regulates B cell-fate dynamics
(A) Irf4-inducible (Irf4/) SWHEL donor B cells transplanted into CD45.1Rosa
M2rtTA/+ hosts and immunized with HEL2XSRBC. Mice were administered water
lacking DOX (DOX), containing DOX throughout the 5 day experiment (+ DOX ‘‘sustained’’) or containing DOX for the first 2 days only (+ DOX ‘‘pulse’’). Five days
after immunization, donor-derived antigen specific cells were identified and analyzed as in Figure 2A.
(B) Representative HEL-specific IgG ELISpot analysis from experiments in (A).
(C) Cells described in (A) were sorted and RNA was analyzed as in Figure 2B, the data represents the average ± SEM of three individual mice.
(D) Irf4-inducible (Irf4+/+) HEL-specific SWHEL donor B cells transplanted into CD45.1, Rosa
M2rtTA/+ hosts and immunized with HEL3XSRBC. Mice were admin-
istered DOX as indicated in (A). Five days after immunization, donor-derived antigen-specific cells were identified and analyzed as in Figure 2A.
(E) Representative HEL-specific IgG ELISpot analysis from experiments in (D). Representative results from two independent experiments are shown; see Fig-
ure S3 for quantitation.
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of IRF4hiBcl6- and Ig-secreting plasma cells (Figures 3A and
3B; Figure S3D). We note that rescued B cells secreted HEL-
specific IgG demonstrating that sustained expression of IRF4
restored both CSR and secretory function (Figure 3B; Fig-
ure S3D). Importantly, transgenic expression of IRF4 also
rescued thegeneration ofBcl6+GCBcells (Figure 3A; FigureS3B
and S3C). Strikingly, ‘‘pulsed’’ induction of IRF4 led only to the
emergence of Bcl6 expressing GC B cells (Figure 3A; Figure S3B
and S3C) that also expressed Aicda but not Pou2af1 transcripts
(Figure 3C). Importantly, plasma cells did not develop under
these conditions (Figure 3A and 3B; Figure S3D). We note that
theHEL-specific IgMspots observedwith Irf4/ cellsmost likely
emanate from host-derived B cells because they are also seen in
mice immunized with mock-conjugated SRBC (Figure S3D; data
not shown). Thus, following antigen encounter, a transient burst
of IRF4 expression appears sufficient to enable the generation
of a stable population of GC B cells that express Bcl6 and AID.
Next, we tested whether increased expression of IRF4 in WT
B cells might promote plasma cell differentiation at the
expense of GC B cells. To do so, we adoptively transferred
Irf4-inducible SWHEL B cells on the Irf4
+/+ background into
CD45.1+Rosa+/M2rtTA congenic mice, immunized with HEL3X
and administered DOX in the drinking water (Figure S3E).
Remarkably, SWHEL responders in the ‘‘sustained’’ DOX group
were impaired in their ability to generate Bcl6+ cells (Figure 3D;
Figures S3B and S3C). DOX-mediated induction of the Irf4 trans-
gene led to an increase in IRF4hi expressing cells and was
accompanied by a corresponding increase in HEL-specific922 Immunity 38, 918–929, May 23, 2013 ª2013 Elsevier Inc.plasma cells (Figure 3E; Figure S3H). Interestingly, the increase
in plasma cells was predominantly observed in the IgM class
of HEL-specific cells (Figure S3H), as predicted by our model
in which high IRF4 concentrations prevent durable AID expres-
sion. Thus transient induction of IRF4 is sufficient to induce the
GC program. In contrast, sustained and higher concentrations
of IRF4 terminate the GC program while promoting the genera-
tion of plasma cells.
Genomic Targeting Analysis of IRF4 and PU.1 in an
Antigen-Dependent Differentiation System
To gain insight into IRF4 regulation of distinct programs of B cell
gene expression, we performed ChIP-seq analyses in an anti-
gen-specific in vitro system that results in CSR and efficient
plasma cell differentiation (Figures S4A and S4B) (Sciammas
et al., 2011). IRF4 expression is induced under these conditions
with BCR engagement and exhibits a wide range of cellular con-
centrations at day 1 (Figure S4C). By day 3, a bimodal pattern of
IRF4 expression is observable with cells expressing either low or
high concentrations of IRF4, which correspond to those under-
going CSR or differentiating into plasma cells, respectively
(Sciammas et al., 2006, 2011). We reasoned that kinetic analysis
of the genome binding landscape of IRF4 in this cellular system
might reveal a relationship between its differing concentrations
and the regulation of distinct programs of gene expression. We
note that these conditions do not promote the generation of
GC B cells; however, given that AID is expressed and functions
to promote SHM in these cells (Sciammas et al., 2011), we hy-
pothesized that some molecular features of GC B cell
Immunity
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amounts of IRF4.
To analyze distinct modes of IRF4 genome targeting, we per-
formed parallel ChIPseq analyses with its major interaction part-
ner, PU.1 (Eisenbeis et al., 1995). This comparison enabled us to
identify genomic regions that were targeted by IRF4 in conjunc-
tion with or in the absence of PU.1 (Figures S4A and S4D). Table
S1 reports the details of sample processing with regard to
sequencing, alignment and peak calls. The overall distribution
of genomic sites of these two transcription factors is shown in
Figure S4E and revealed that the majority of binding events
were extragenic and occurred within 100 kbp of the nearest
TSS. A small number of binding peaks were randomly chosen
and validated by ChIP (Figure S4F).
To analyze the dynamics of IRF4 and PU.1 binding, we
compiled coincident peaks between the day 1 and day 3 data
sets (Figure S4D). Temporally-specific binding events were
observed for both IRF4 and PU.1, suggesting that a shift in the
genome binding landscape is associated with the bimodal
expression of IRF4. Next, we determined the extent to which
IRF4 targets the genome with or without PU.1 (Figures 4A and
4B). IRF4 cobound with PU.1 at a majority of the genomic sites.
A third of IRF4 binding eventswere not associatedwith PU.1; this
mode of IRF4 genome targeting is denoted IRF4 (not PU.1).
Comparison of our data with DNaseI seq analysis in naive B cells
(ENCODE data, Figure S4G) revealed 90% of IRF4 (and PU.1)
cotargeted regions (days 1 and 3) to be contained within DNaseI
hypersensitive sites in naive B cells demonstrating that EICE
motifs are located in accessible chromatin. In contrast, IRF4
(not PU.1) regions overlapped with %50% of the DNaseI sites
present in naive B cells suggesting that this mode of IRF4
genomic targeting involved the de novo establishment of acces-
sible regions.
Distinct DNA Motifs Comprise the IRF4 Cistrome
We searched for overrepresented sequence motifs by using the
MEME pattern-finding algorithm in the IRF4 cistrome (Figures 4A
and 4B). Within the IRF4 (and PU.1) bound regions, the EICE
motif occurred with an incidence approaching 100%. This
finding demonstrated the fundamental importance of the EICE
motif in recruitment of IRF4 by PU.1 to genomic sites in differen-
tiating B cells.
In contrast, within IRF4 (not PU.1)-bound regions, two distinct
DNA motifs were enriched (Figure 4B). The first represented the
ISRE, which is composed of two IRFmotifs (GAAA) separated by
two base pairs. The second motif was a canonical AP-1 motif
that was often found near the peak’s summit (Figure S4I). Inspec-
tion of the surrounding sequences identified an IRF motif (GAAA)
either abutting or separated by four nucleotides from the AP-1
motif (Figure 4B; Figure S4H) suggesting the presence of an
AP-1-IRF composite element (AICE) (Glasmacher et al., 2012).
Accordingly, we found that BATF and IRF4 cobound to a sam-
pling of these AICE motifs in B cells (Figure S4K). Thus, the
IRF4 cistrome in B cells comprises three distinct DNA binding
modes characterized by EICE, AICE, and ISRE motifs.
Within the IRF4 (not PU.1) peaks, the incidence of AICE and
ISRE motifs was inverted between the day 1 and day 3 time
points, and the ISRE predominated at day 3 (Figure 4B). This
demonstrates that the nature of the IRF4 binding landscapeshifts during the process of B cell differentiation, and the higher
concentration of IRF4 is accompanied by increased occupancy
of ISRE motifs.
IRF4 Binds the ISRE as a Dimer with Lower Affinity
Given the above finding, we analyzed the relative affinity of IRF4
for the ISRE and EICE motifs. An ISRE motif from Prdm1 CNS9
(Sciammas et al., 2006) was used in electrophoretic mobility shift
assays (EMSAs) (Figure 4C). IRF4 generated a protein-DNA
complex (Figure 4C) that was competed by WT competitor
DNA, but not ones in which one or both of the IRF sites were
mutated. This suggested that IRF4 bound the ISRE as a dimer,
which was confirmed by analyzing the migration of the protein-
DNA complexes formed by mixing two different carboxy-termi-
nal truncations of IRF4 (Figure S4J). Thus IRF4 binds the ISRE
as a homodimer in contrast with its binding to an EICE as a het-
erodimer with PU.1 or to an AICE as a heterotrimer with a BATF-
containing AP-1 complex.
To determine the relative affinity of IRF4-PU.1 heterodimeric or
IRF4 homodimeric complexes for the EICE versus ISRE motifs,
respectively, we analyzed binding over a wide range of IRF4
concentrations (Figures 4D and 4E). Whereas increasing IRF4
concentration in the presence of PU.1 resulted in saturation of
IRF4 binding to the EICE, saturation was not observed for IRF4
binding (in the absence of PU.1) to the ISRE within the concen-
tration range that was tested. These data demonstrated that
IRF4 binds with higher affinity to EICE motifs as a heterodimer
with PU.1 than to ISRE motifs as a homodimer and suggest
that IRF4 is able to occupy EICE motifs at a lower concentration
in vivo. Thus, higher IRF4 concentrations would be needed to
drive binding onto ISRE motifs, and this is consistent with their
increased utilization in differentiating IRF4hi B cells at day 3 (Fig-
ure 4B; Figure S4C).
IRF4 Targeting of the Prdm1 Locus
Our previous analysis had suggested that IRF4 directly activates
Prdm1 transcription to enable plasma cell differentiation. The
ChIP-seq analysis confirmed that IRF4 bound to the CNS9 re-
gion in Prdm1 (Figure 5A; Figure S5A). In addition, we identified
multiple peaks surrounding the Prdm1 gene that increased in in-
tensity at day 3 (Figure S5A). Because IRF4 is necessary for pro-
moting Blimp1 expression, we reasoned that IRF4 binding to the
Prdm1 locus may be required for the deposition of activating
H3K4me1 and H3K27Ac chromatin marks. Analysis of WT B
cells showed that these chromatin marks were present at low
levels at some of these regions at the day 0 and day 1 time points
but sharply increased at day 3 when Prdm1 was maximally ex-
pressed (Figure S5B). In the absence of IRF4, these marks failed
to accumulate not only at IRF4-targeted but also at nontargeted
regions that included thePrdm1 promoters (Figure S5C). Overall,
this analysis demonstrates an extensive targeting landscape of
IRF4 at the Prdm1 locus that includes both IRF4 (and PU.1)
and IRF4 (not PU.1) binding modes. Importantly IRF4 binding
to multiple sites at the Prdm1 locus appears to be required for
the acquisition of an activated chromatin state.
IRF4 Targeting of Bcl6 and Pou2af1 Loci
Because Bcl6 and Pou2af1 expression is also dependent on
IRF4, we sought to determine whether it targeted these genes.Immunity 38, 918–929, May 23, 2013 ª2013 Elsevier Inc. 923
Figure 4. Analysis of IRF4 Cistrome in Antigen-Activated B Cells Reveals Three Distinct Motifs and Binding Modes
(A and B) B cells from B1-8i anti-NP knockin mice were stimulated with NP-Ficoll, CD40L, and interleukin-2 (IL-2), IL-4 and IL-5. On days 1 and 3, chromatin was
crosslinked and processed for IRF4- and PU.1-specific ChIP coupled to massively parallel sequencing. Left panels display the union analysis of the number of
IRF4 (and PU.1) or IRF4 (not PU.1) binding peaks, respectively, at day 1 or Day 3 after B cell stimulation. Right panels display overrepresented sequence motifs
revealed byMEME in Logo format. The associated pie charts indicate the number of regions analyzed and the frequencywithwhich themotif is found. EICE, ISRE,
and AICE represent the Ets-IRF composite element, interferon sequence response element, and AP-1-IRF composite element, respectively.
(C) IRF4 binds with lower affinity to ISRE motifs than to EICE motifs. EMSA with the Blimp1 CNS9 ISRE sequence as probe. All binding reactions contained a WT
probe and nuclear extract from IRF4-expressing 293T cells. Increasing amounts of competitor DNAs, WT, or mutant ISREs, were included as indicated. Anti-IRF4
or control antibodies were used in supershift assays to confirm identity of the IRF4 complex.
(D) Binding saturation curves of IRF4 to EICE or ISREmotifs. Binding reactions using the EICE DNA probe derived from the Ig Kappa 30 enhancer were carried out
in the presence of a constant amount of PU.1 protein. IRF4 protein was increased in 2-fold increments as indicated. The ISRE probe and binding reactions were
conducted as in (C). Positions of relevant protein-DNA complexes are indicated by arrows.
(E) Densitometry analysis of (D). Data in (C) and (D) are representative of three independent experiments. See also Figure S4.
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IRF4 Regulates GC B Cell-Fate DynamicsIRF4 bound to a region 24 kbp upstream of the Bcl6 gene (Fig-
ure 5B) and to several sites within the first intron. Notably, at the
upstream position, PU.1 was found to cobind with IRF4 and this
region coincided with a DNaseI hypersensitive site (Figure 5B;
Figure S5D). We did not find evidence of IRF4 targeting the
Bcl6 promoter as was shown in human B lymphoma cell lines
(Saito et al., 2007). There were two prominent IRF4 (not PU.1)
peaks within the first intron of Pou2af1 gene (Figure 5C). IRF4
binding to sites in the Bcl6 and Pou2af1 genes diminished from924 Immunity 38, 918–929, May 23, 2013 ª2013 Elsevier Inc.day 1 to day 3 of B cell activation as compared with its occu-
pancy of the Prdm1 locus, which underwent an increase. To
confirm targeting of the Bcl6 and Pou2af1 genes by IRF4 in GC
B cells, we performed ChIP analysis with such cells isolated
from immunizedmice. We observed binding of IRF4 to the afore-
mentioned regions of the Bcl6 and Pou2af1 genes (Figure 5D).
Thus these data, along with those in Figure 2B, demonstrate
that IRF4 directly targets and activates the expression of key reg-
ulatory genes that are required for GC B cell differentiation.
Figure 5. IRF4 Targets the Prdm1, Bcl6, and Pou2af1 Genes
(A–C) ChIP-seq tag enrichment (y axis) is displayed as a histogram for the (A) Prdm1 (Blimp1), (B) Bcl6, and (C) Pou2af1 (Obf1) loci at indicated time points for
antigen-activated B cells described in Figure 4. The x axis indicates the genomic interval (build mm9). The lowermost histogram in each panel shows genomic
accessibility within naive CD19+ WT B cells, as assessed by DNaseI-seq (data downloaded from ENCODE).
(D) IRF4 binding to theBcl6 and Pou2af1 loci in purified GCB cells. Enrichment values (% input chromatin) with control IgG, IRF4, and PU.1 antibodies are shown
for indicated genomic regions: CNS1 (negative control), Bcl6, Pou2af1, and Igkappa 30 enhancer (positive control). The average enrichment and SEM is from two
independent experiments. See also Figure S5.
Immunity
IRF4 Regulates GC B Cell-Fate DynamicsDivergent IRF4 Binding Modes Correlate with
Complementary Patterns of Gene Activity
We next analyzed how the distinct modes of IRF4 targeting
correlate with IRF4 dependent gene expression programs that
are reflective of the ‘‘GC-like’’ and plasma cell states. Thus we
performed genome-wide transcriptome analyses and compared
WT or Irf4-inducible B cells (Sciammas et al., 2011) on the Irf4/
background.
We reasoned that we could relate distinct patterns of gene
expression to divergent modes of IRF4 genome targeting by
analyzing the expression changes between cellular conditions
in which IRF4 is expressed to varying extents at the different
time points. To this end, we employed Expectation Maximization
of Binding and Expression Profiles (EMBER) (Maienschein-Cline
et al., 2011), which uses an unsupervised machine learning algo-
rithm to infer target genes from transcription factor binding and
expression data. EMBER scores genes that are likely regulated
by a given transcription factor within 100 kpb of its binding peaks
based on their conforming to an overrepresented gene expres-
sion pattern (see Supplemental Information for further details).
We applied EMBER to the IRF4 (and PU.1) and IRF4 (not PU.1)
peaks at the day 1 and day 3 time points (Figures 4A and 4B). The
EMBER analysis is shown in Figure 6A and Table S2. The
numbers in the upper left hand boxes of each graph indicate
the number of peaks that were assigned at least one target
gene (Figure 6A). Roughly half of all genome targeting events
(compare to the number of peaks in Figures 4A and 4B) scored
above a statistical threshold (see Supplemental Information).
To simplify analysis of the gene expression data, we binned dif-
ferential expression between pairwise sample comparisons into
five categories: (++) large upregulation, (+) small upregulation, (0)
no change, (–) small downregulation, and (– –) large downregula-
tion (see Supplemental Information). Each of the pairwise geneexpression comparisons are plotted against the log-likelihood
ratio of finding a given differential expression pattern. IRF4
peak-associated trends in differential gene expression are repre-
sented as changes in the relative sizes of colored bars corre-
sponding to each of the five bins of differential expression. For
example, in Figure 6A, in the IRF4 (and PU.1) day 1 expression
pattern (top left), the large bright green bars in the fourth, fifth,
and sixth columns indicate that the majority of inferred target
genes tend to be strongly downregulated in the presence of
IRF4 (either in WT cells or in Irf4/ cells after restoration of
IRF4 expression with DOX). Conversely, the much smaller red
bars in the same columns indicate that very few of the inferred
gene targets are strongly upregulated in the presence of IRF4.
EMBER analysis revealed three dominant patterns of tran-
scriptional control by IRF4 (and PU.1) binding versus IRF4 (not
PU.1) binding events (Figure 6A). In the first pattern, inferred
target genes associated with IRF4 (and PU.1) binding tended
to be repressed regardless of time point (the green bars corre-
sponding to mild and strong repression are large). This unex-
pected finding is consistent with an IRF4-dependent manner of
regulation because (1) these genes were derepressed in the
absence of IRF4 and (2) the same genes were repressed when
IRF4 expression was restored by DOX-mediated induction of
the inducible allele of Irf4 in Irf4/ B cells (Figure 6A). In the sec-
ond pattern, genes associated with IRF4 (not PU.1) binding were
preferentially activated at day 1. The third pattern comprises a
mixture of up- and downregulated targets of IRF4 (not PU.1)
on day 3. We note that the transition in the nature of transcrip-
tional output accompanies both the change in IRF4 concentra-
tion (Figure S4C) as well as the differentiation state of these cells
(Figure S4B). Collectively, this analysis shows that IRF4 (not
PU.1) genome targeting, regardless of time, is associated with
markedly different behaviors of gene expression compared toImmunity 38, 918–929, May 23, 2013 ª2013 Elsevier Inc. 925
Figure 6. IRF4 (and PU.1) and IRF4 (not
PU.1) Genome Targeting Are Associated
with Distinct Patterns of Transcriptional
Regulation
(A) Genome-wide expression data was derived
from purified B cells isolated from WT (Irf4+/+),
mutant (Irf4/), or Irf4-inducible mice that were
stimulated with CD40L and cytokines. Total RNA
was isolated on days 1 and 3 and processed for
Affymetrix arrays. B cells from the Irf4-inducible
mice were also cultured in the presence of
16 ng/mL or 100 ng/mL doxycycline (DOX) to
induce the expression of the Irf4 transgene, indi-
cated by the shaded gradients on the x axis.
EMBER expression patterns for the four peak
combinations (IRF4 at days 1 and 3 with and
without PU.1). The numbers in the upper lefthand
boxes of each graph indicate the number of peaks
that scored above a threshold and were assigned
at least one target gene. The x axis displays pairwise comparisons between expression measurements (specifically WT cells versus Irf4/ cells or Irf4-inducible
cells (on the Irf4/ background) with and without DOX). The size of each bar in the y axis indicates the significance of changes in expression and the color
indicates the nature of the change; see (Maienschein-Cline et al., 2011) for further details.
(B) Day 3 inferred target gene expression in the context of ex vivo antigen specific GC B cell and plasma cell transcriptomes (from NCBI GEO). Data presented as
in (A). See also Figure S6.
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IRF4 Regulates GC B Cell-Fate Dynamicsthose associated with IRF4 (and PU.1) genome targeting, sug-
gesting that each binding mode functions to control distinct
developmental programs.
Divergent IRF4 Binding Modes Correlate with Distinct
Developmental Programs
To substantiate the hypothesis that IRF4 (and PU.1) and IRF4
(not PU.1) modes of genome targeting regulate different
developmental programs, we tested whether the expression
patterns of inferred target genes obtained from differentiated
cells at the day 3 time point correlated with plasma cell or GC
B cell states. To perform this analysis, we used transcriptome
experiments derived from ex vivo sorted antigen-specific
plasma cells and GC B cells (Luckey et al., 2006). By using these
data from GEO, we compared GC B cell and plasma cell tran-
scriptomes and classified differential gene expression by using
the same discrete binning scheme as above (++, +, 0, –, – –).
Then, by using inferred target genes from either IRF4 (and
PU.1) or IRF4 (not PU.1) day 3 peaks, we computed the log
odds ratio of finding preferential expression of these genes
in plasma cells or GC B cells (Figure 6B; Figure S6A; Table S2).
With some exceptions, we found that the majority of IRF4
(and PU.1) inferred target genes were expressed at lower levels
in plasma cells compared to GC B cells (large yellow bar). In
contrast, inferred target genes associated with IRF4 (not PU.1)
binding at day 3 enriched for a substantial set of genes that
were expressed at higher levels in plasma cells compared
to GC B cells (large bright blue bar). Similar trends were
observed when we analyzed the naive to GC B cell and the naive
to plasma cell transitions (Figures S6B and S6C). These data
indicate that, during the transition of a naive or GC B cell to a
plasma cell, both IRF4 (and PU.1) and IRF4 (not PU.1) binding
events are associated with the repression of GC genes. In
contrast, IRF4 (not PU.1) binding, particularly to the ISRE motif
seems to preferentially function in activation of the PC program
of gene expression. The proposed functions of these distinct926 Immunity 38, 918–929, May 23, 2013 ª2013 Elsevier Inc.modes of IRF4 genome targeting in relation to its intracellular
concentrations and B cell fate dynamics are depicted in
Figure S7.
To further corroborate the finding that each binding mode is
controlling distinct developmental programs, we determined
whether the inferred target genes controlled by IRF4 (and
PU.1) and IRF4 (not PU.1) genome targeting were associated
with different functional classes of genes. Whereas genes asso-
ciated with IRF4 (and PU.1) binding enriched for immune and
inflammatory response categories, the IRF4 (not PU.1)-associ-
ated genes enriched for cell biological categories including
endoplasmic reticulum functions (Figure S6D; Table S3). Many
of these latter genes are important for the differentiation of
specialized secretory cells suggesting that the IRF4 (not PU.1)
targeting mode involving ISREs specifies the functional state of
plasma cells.
DISCUSSION
We have demonstrated an essential and cell-intrinsic role for
IRF4 in generating GC B cells. IRF4 does so in part by activating
expression of the Bcl6 and Pou2af1 genes. Our combined ge-
netic analyses involving conditional deletion of the Irf4 gene prior
to B cell activation as well as its transient expression by using the
Irf4-inducible allele define the temporal requirement for IRF4 in
promoting GC B cell fate to the first few days after antigen
encounter. The results strongly suggest that IRF4 is required
for initiation, but not maintenance of the GC state, and the latter
is dependent on sustained expression of Bcl6. It follows that
IRF4 is required for the activation but notmaintenance of expres-
sion of the Bcl6 gene. In contrast, expression of the Pou2af1
gene appears to continuously depend upon IRF4. Intriguingly,
the latter gene along with IRF4 also functions in regulating
plasma cell differentiation (Corcoran et al., 2005). Given that
high and sustained expression of IRF4 antagonizes the GC state,
these findings account for transient action of IRF4 in generating
Immunity
IRF4 Regulates GC B Cell-Fate DynamicsGC B cells and its downregulation in such cells. It will be inter-
esting to determine whether in GC B cells negative feedback
by Bcl6 serves to directly repress the Irf4 gene, as has been
observed in cell lines (Alinikula et al., 2011).
Our key conclusion that IRF4 functions in a cell-intrinsic
manner to regulate GC B cell differentiation differs from that
reached by a recent report (Bollig et al., 2012). We note that
our findings are based on the use of three distinct alleles of
Irf4: germline, conditional, and tet-inducible. Importantly, the
Irf4-conditional allele (Irf4fl/fl) displays a GC B cell defect when
CRE expression is driven by the CD19 locus but not by the
Cg1 locus. Finally, the tet-inducible Irf4 allele allowed us to
unambiguously demonstrate that Bcl6 and AID expression can
be induced in Irf4/B cells in an IRF4-dependent manner. Bollig
et al. demonstrate a role for IRF4 in T follicular helper cell differ-
entiation. We therefore propose that IRF4 may direct T follicular
helper cell differentiation by directly activating Bcl6 expression,
as is the case in B cells.
By using genome-wide analysis in a model system involving
antigen-dependent B cell differentiation, three distinct modes
of IRF4 binding to its target sequences have been delineated.
The dominantmode (representing two thirds of the total) involves
cobinding of IRF4 with PU.1 to EICE motifs. Two additional
modes, both of which are PU.1 independent, involve IRF4 bind-
ing to either an ISRE or AICE motif. Co-occupancy of the EICE
motif by PU.1 and IRF4 is associated with regulation of genes
involved in B cell activation and function. Molecular redundancy
between PU.1 and SpiB in the Ets family, as well as between
IRF4 and IRF8 in the IRF family, can result in the targeting of
the EICEmotif by four distinct Ets-IRF ternary complexes (Eisen-
beis et al., 1995). Accordingly, these complexes can play either
redundant or unique roles in B cell development, activation,
and terminal differentiation. Importantly, although IRF4 and
IRF8 function redundantly in the differentiation of pre-B cells
(Lu et al., 2003), IRF4 is uniquely required for the GC response
and plasma cell differentiation (Feng et al., 2011; Klein et al.,
2006; Sciammas et al., 2006). Given that SpiB is uniquely impor-
tant for the differentiation of GC B cells along with the observa-
tion that IRF8 is expressed at high levels in GC B cells, it will
be interesting to determine whether occupancy of the EICEmotif
in this cellular context shifts to these factors.
A second mode of IRF4 binding is observed on composite
AP-1-IRF motifs (AICE). This unusual motif has been observed
by us in the context of T cells, where it functions as the domi-
nant mode of IRF4 genomic targeting, given that these cells
do not express PU.1 or SpiB (Glasmacher et al., 2012). We
have demonstrated that this composite motif directs coopera-
tive binding of IRF4 with BATF heterodimers belonging to
the AP-1 family. As Batf/ B cells partially phenocopy Irf4/
B cells (Betz et al., 2010; Ise et al., 2011), it will be informative
to analyze the molecular consequences of IRF4-BATF family
complexes that assemble on AICE motif-containing genes. In
accord with a signal-dependent mode of gene regulation by
AP-1 family members, the AICE motif is observed at high inci-
dence in DNA bound regions at the day 1 time point, soon after
BCR signaling initiated by antigen encounter. At this time point,
B cells are forming blasts and initiating the gene regulatory
programs necessary for subsequent differentiation. The inte-
gration of IRF4 with the AP-1 system at this stage, both ofwhich are controlled by BCR signaling, suggests that they
could be important for effecting the downstream transcriptional
responses that are triggered by differential BCR signaling;
i.e., low- or high-affinity antigen or levels of coreceptor
engagement.
The third mode of IRF4 binding in the B cell genome involves
classical ISREs. We demonstrate that IRF4 binds the ISRE as a
homodimer, and this interaction is of lower affinity than the
PU.1-IRF4 interaction with the EICE motif. Accordingly, binding
to the ISRE is preferentially observed at the day 3 time point of
B cell differentiation when IRF4 protein levels peak. The day 3
time point represents a stage where a majority of the B cells in
the culture system have undergone differentiation into plasma
cells. Intriguingly, the increased usage of the ISRE in plasma
cells suggests an association of this regulatory element with
structural genes important for their differentiation. Indeed, such
target genes are enriched for those that encode secretory func-
tions. Although the concept of differing concentrations of a tran-
scription factor regulating distinct cell fates has been suggested
to be widely operative in mammalian cell differentiation (see De-
Koter and Singh, 2000), its molecular basis has proven difficult to
elucidate. Our results provide an appealing molecular explana-
tion for the requirement of higher concentrations of IRF4 in regu-
lating plasma cell differentiation by enabling occupancy of low
affinity ISRE motifs that are associated with plasma cell genes.
Based on experimental and mathematical analyses, we have
proposed a mechanism of kinetic control in which the initial
rate of IRF4 accumulation, driven by the strength of BCR
signaling, controls a gene regulatory network that orchestrates
cell fate decisions between cells undergoing CSR, a ‘‘GC-like’’
state, versus cells differentiating into plasma cells (Sciammas
et al., 2011). In this model, low affinity or avidity antigen interac-
tions with the BCR favor a longer duration of a ‘‘GC-like’’ state
before plasma cell differentiation. In contrast, high affinity or
avidity antigen interactions with the BCR limit the period of
time in which AID is expressed and therefore promote plasma
cell generation accompanied with relatively low levels of CSR
and SHM. Herein, we corroborate and extend this regulatory
model. Specifically, as evidenced by the ‘‘pulsed’’ experiment,
we propose that transient expression of IRF4 in GC B cells
(IRF4loBcl6+) serves to ‘‘reset’’ the mechanism of kinetic control
initiated by the first exposure to antigen. Hence, kinetic control
would be reinstated during positive selection of somatically hy-
permutated GC B cells upon their interaction with antigen dis-
played by follicular dendritic cells. Specifically, those clones
accumulating mutations that confer higher affinity to their BCR
would induce increased levels of IRF4 expression, both as a
function of BCR signaling and CD40 signaling by T helper cells,
and thus differentiate into plasma cells. In support of this notion,
it has been found that post-GC plasma cells are preferentially en-
riched for high affinity SHM-dependent mutations (Phan et al.,
2006; Smith et al., 1997). In contrast, those clonotypes exhibiting
lower affinity conferring mutations would induce lower levels of
IRF4 expression and differentiate intomemory B cells or undergo
new rounds of SHM and selection (Smith et al., 1997; Victora
et al., 2010). Given that GC B cells express high amounts of
Bcl6, it will be interesting to determine whether selection into
the high affinity cell pool involves a steeper magnitude of IRF4 in-
duction to overcome repression by Bcl6.Immunity 38, 918–929, May 23, 2013 ª2013 Elsevier Inc. 927
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Mice
The generation of the Irf4/ and Irf4-inducible mice has been previously
described (Mittru¨cker et al., 1997; Sciammas et al., 2011). The B1-8i gene tar-
geted mice were a generous gift of K. Rajewsky. SWHEL mice have been pre-
viously described (Phan et al., 2005) andwere used to cross to Irf4/mice and
Irf4-inducible mice. Conditional Irf4fl/fl mice (Klein et al., 2006) were crossed to
CD19+/CRE mice. Mice were housed in specific pathogen-free conditions and
were used and maintained in accordance of the Institutional Animal Care and
Use Committee guidelines.
ChIP and ChIP-Seq
ChIP was performed by using anti-IRF4, -PU.1, -H3K4me1, -H3K27Ac, and
control IgG antibodies (Santa Cruz Biotech. and Abcam) (Sciammas et al.,
2006). For massively parallel sequencing, 200 mg of chromatin fragments
were immunoprecipitated by using anti-IRF-4 and anti-PU.1 antibodies, and
DNA libraries were prepared. DNA was sequenced by using the Illumina
GA2, data was processed with the Solexa pipeline package, and sequences
were aligned to the mouse genome (mm9) by using ELAND software. Further
details are available in the Supplemental Information.
Generation of Mixed Bone Marrow Chimeric Mice and SRBC
Immunization
Bone marrow was collected from the long leg bones of WT CD45.1/2 hetero-
zygous mice and from Irf4+/+ or Irf4/ (both CD45.2) mice and mixed
together in equal numbers. Cells were injected into irradiated (2 3 550
rads) WT CD45.1 mice. Eight weeks after adoptive transfer, mice were immu-
nized with sheep RBC (Lampire Biologicals) intraperitoneally, and the GC
response was quantified by flow cytometry 7 days later. Conditional Irf4fl/fl
mice were bred to CD19C+/CRE, immunized with SRBC, and spleens were
analyzed 14 days later. Further details are available in the Supplemental
Information.
Adoptive Transfer of SWHEL B Cells
SWHEL mice were crossed to Irf4-inducible or Irf4
/mice and used for adop-
tive transfer experiments using established methods (Phan et al., 2005). Dox-
cycline (DOX, Sigma) was administered in drinking water that contained 1%
(w/v) sucrose, at a concentration of 0.5 mg/mL; the control group was fed su-
crose water only and the ‘‘pulse’’ group was changed to sucrose water only
after the initial DOX treatment. Further details regarding CFSE labeling,
numbers of transferred cells, SRBC-conjugated antigens, and sorting are
available in the Supplemental Information.
Flow Cytometry and ELISpot Assays
RBC-depleted spleen cell suspensions were prepared, stained, and analyzed
on the LSR II flow cytometer, and the resulting data was processed by using
FlowJo software (Tree Star, Inc.). HEL+ cells were identified as described
(Phan et al., 2005). Detection of Bcl6 was performed by fixing and permeabi-
lizing cells with Fix/Perm staining kit (eBioscience) and staining with anti-Bcl6
(BD). Detection of IRF4 was performed as previously described (Sciammas
et al., 2011). For ELISpot analysis, total splenocytes were cultured for 6 hr
on plates coated with HEL (Sigma) and processed with anti-IgM and anti-
IgG antibodies as previously described (Sciammas et al., 2006). Further details
are available in the Supplemental Information.
RNA Preparation, Microarray, and RT-PCR Analysis
For transcriptome analysis, total RNA was prepared from triplicate cell sam-
ples by using Trizol and processed for hybridization to Affymetrix mouse
430A chips by using standard procedures. For qRT-PCR analysis of sorted
SWHEL B cells, total RNA was prepared by sorting 5,000 cells directly into
RLT buffer from the RNeasy Micro Kit (QIAGEN). Further details are available
in the Supplemental Information.
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